Under the leadership of Prof. Tang Shengbin, the company`s R&D team, through unremitting efforts, has screened and nurtured a new cultivar of Epimedium with high content and yield from more than a dozen wild Epimedium species. The average content of glycosides can reach 2.5% or more, which is 5 times the lower limit of the Chinese Pharmacopoeia (the Pharmacopoeia stipulates that the amount of icariin should not be less than 0.5%), and the yield can reach 300 kg/mu or more. It has been transplanted into Daejeon and is expected to grow to 1,000 acres in 3 to 5 years. With the successful cultivation and large-scale development of new products of Epimedium, our company will certainly dominate the icariin market in the field of plant extracts.
Copyright © 2021 Chongqing Taisun Pharmaceutical Co., Ltd. All rights reserved.